Constructing Singlet Oxygen “Slow Release” Platform to Optimize the Performance of Commercial Photosensitizers

Abstract

Commercial photosensitizers (PSs) present great potential in the field of clinical photodynamic therapy (PDT) yet face a formidable challenge owing to the extremely short lifespan of singlet oxygen (1O2). Herein, the 1O2 slow‐release “platform” is proposed based on an anthracene‐groups functionalized D‐π‐A system (AIC), which can capture and slowly release 1O2 produced by commercial PSs. Meanwhile, the reversible chemical process between AIC and 1O2 is demonstrated by a series of optical experiments and high‐resolution mass spectrum. Remarkably, by virtue of 1O2 slow‐release “platform”, the sustaining mitochondrial autophagy and cell apoptosis still take place when the laser is cut off with a short period of irradiation, reducing the side effect of sustained irradiation. In general, the construction of 1O2 slow‐release platform opens up exciting opportunities for improving the PDT effect of commercial PSs.

Unveiling the Impact of Light-Induced Acceptor-Generated ROS on Device Stability in Organic Photovoltaics

“…10 μL of TEMP was added to 100 μL of LC8 and BC8 aggregation without and with white light irradiation (0.5 W/cm 2 ) for 3 min. Finally, the EPR signals were recorded at room temperature . An Agilent 7000E triple quadrupole gas chromatography – mass spectrometry (GC-MS) system was utilized to separate and detect reactive oxygen species (ROS).…”